Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * For participants under the age of 18 years, documentation of adolescent assent by the participant and consent of both parents or guardian * Adults aged \>= 18 years * Adolescent patients aged \>= 16 years and \< 18 years weighing at least 45 kg who have no other standard-of-care option for treatment * Eastern Cooperative Oncology Group (ECOG) =\< 2 * Patients with histologically confirmed AML, according to World Health Organization (WHO) criteria, with refractory/relapsed (R/R) disease following a venetoclax-containing regimen who are ineligible for therapies known to be effective for treatment of their AML. * Patients with extramedullary disease may be included if they also have marrow involvement * Patients with acute promyelocytic leukemia (APL) will not be eligible * Fully recovered from the acute toxic effects (except alopecia) to =\< grade 1 of prior anti-cancer therapy * Ability to swallow pills * Absolute neutrophil count (ANC) \>= 750/mm\^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated) * NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement * White blood cell (WBC) =\< 25 x 10\^9/L prior to initiation of study therapy. Cytoreduction with hydroxyurea prior to treatment and/or during cycle 1 may be required (performed within 14 days prior to d…